Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY1143572 |
Synonyms | |
Therapy Description |
Atuveciclib (BAY11435720) is a selective PTEFb/CDK9 inhibitor that potentially decreases proliferation and induces apoptosis in tumor cells (Cancer Res, August 1, 2015 75; DDT02-02, PMID: 31384397). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY1143572 | Atuveciclib|BAY 1143572 | CDK9 Inhibitor 21 | Atuveciclib (BAY11435720) is a selective PTEFb/CDK9 inhibitor that potentially decreases proliferation and induces apoptosis in tumor cells (Cancer Res, August 1, 2015 75; DDT02-02, PMID: 31384397). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02345382 | Phase I | BAY1143572 | Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia | Completed | USA | DEU | 0 |
NCT01938638 | Phase I | BAY1143572 | Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | Completed | USA | 3 |